Si­lence’s siR­NA can­di­date for car­dio­vas­cu­lar dis­ease con­tin­ues to de­liv­er in Phase 2 tri­al

Si­lence Ther­a­peu­tics has un­veiled ad­di­tion­al da­ta from a mid-stage tri­al of its siR­NA ther­a­py can­di­date in cer­tain peo­ple at risk of heart episodes, set­ting the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER